Please assess the completion status of the following clinical trial:

Trial Title: A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0 or 1 at study entry.~* Have a histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma.~* Have metastatic disease or locally advanced, unresectable disease.~* Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.~* Have experienced documented objective radiographic or symptomatic disease progression during first-line therapy, or within 4 months after the last dose of first-line therapy with any platinum/fluoropyrimidine doublet for unresectable or metastatic disease.~* Have adequate organ function.~* Have urinary protein ≤1+ on dipstick or routine urinalysis.~Exclusion Criteria:~* Have undergone major surgery within 28 days prior to randomization.~* Have received any first-line chemotherapy other than platinum and fluoropyrimidine with or without anthracycline for advanced gastric or GEJ adenocarcinoma.~* Have received any previous systemic therapy (including investigational agents) targeting vascular endothelial growth factor (VEGF) or the VEGF receptor signaling pathways.~* Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to randomization.~* Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry.~* Have a history of GI perforation and/or fistulae within 6 months prior to randomization.~* Have experienced any arterial thromboembolic event within 6 months prior to randomization.~* Have uncontrolled arterial hypertension (systolic blood pressure ≥160 millimeters of mercury \[mmHg\] or diastolic blood pressure ≥100 mmHg) despite standard medical management.~* Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to randomization.~* Have a serious illness or medical condition(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel (Type: EXPERIMENTAL): 8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met.
- Placebo + 80 mg/m² Paclitaxel (Type: EXPERIMENTAL): Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met.

Based on this trial design, predict the completion outcome and termination type (if applicable).